Scientists Grow First Functional Esophagus in Lab and Transplant It Without Immune Suppression

Scientists at Great Ormond Street Hospital and University College London have grown a functional esophagus in the laboratory and successfully transplanted it into living animals, producing the first complete proof-of-concept that an engineered food pipe can replace a missing section of the organ, contract normally, and allow animals to eat and grow — without requiring the lifelong immune-suppressing drugs that currently burden organ transplant recipients worldwide. The study, published in Nature Biotechnology on March 20, 2026, offers a potential lifeline to the roughly 180 children born in the UK each year with esophageal atresia, a rare birth defect in which the food pipe fails to form properly.

In approximately 10 percent of esophageal atresia cases, the gap between the upper and lower sections of the esophagus is too large to bridge with conventional surgery — a condition known as long-gap esophageal atresia. Children with this diagnosis face repeated hospitalizations, feeding tubes, and complex reconstructive operations that carry high risks of complications. Current surgical alternatives, including using sections of the stomach or colon to replace the missing segment, often produce poor functional outcomes and lifelong digestive problems. The new approach offers something fundamentally different: a personalized, living replacement made from the patient's own cells.

The technique, developed under the leadership of Professor Paolo De Coppi and Dr. Marco Pellegrini at UCL's Great Ormond Street Institute of Child Health, begins with a donor esophagus. Through a process called decellularization, the donor organ is carefully stripped of all its cells using detergent washes, leaving behind only the collagen scaffold — the structural framework that gives the organ its shape. This scaffold is then repopulated with muscle progenitor cells taken from a small biopsy of the intended recipient, which are multiplied in a laboratory bioreactor for one week before being injected directly into the scaffold. The resulting construct is implanted to replace the missing segment.

Eight recipient pigs received the engineered transplants, and all eight survived the critical 30-day post-operative window — a milestone that previous attempts at esophageal tissue engineering had often failed to clear. By the six-month mark, the laboratory-grown grafts had developed functional muscle, nerves, and blood vessels. The transplanted esophagi contracted and relaxed rhythmically, moving food from throat to stomach just as a native organ would. The animals ate normally and grew at healthy rates. Most strikingly, no immunosuppressive drugs were needed: because the graft was seeded with the recipient's own cells, the immune system recognized it as self-tissue.

'Because the graft contains the child's own muscle progenitor cells, it would be recognised as their own tissue,' said Dr. Pellegrini, explaining why the approach sidesteps the toxicity and infection risk of long-term immune suppression. Lead author Dr. Natalie Durkin of GOSH and UCL GOS ICH described the results as 'a major leap towards personalised regenerative treatments for children born with life-threatening oesophageal conditions.' The research team estimated that human clinical translation could be achievable within approximately five years, pending further safety studies and regulatory review.

The implications extend beyond esophageal atresia. The decellularization-repopulation approach used in this study has previously been explored for trachea, bladder, and kidney tissue, but the esophagus — with its complex layered structure of muscle, connective tissue, and mucosa — represented one of the most technically demanding targets. Success here provides a template and a confidence boost for researchers working on other hollow-organ engineering challenges. The study's authors noted that the same principles could potentially apply to other sections of the gastrointestinal tract, opening possibilities for treating children and adults with intestinal failure — a condition that currently leaves many patients dependent on intravenous nutrition for life.